Royalty Report: Drugs, Pharmaceuticals, Therapeutic – Collection: 26802

$100.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • Pharmaceuticals
  • Therapeutic
  • Biotechnology
  • DNA
  • Biological Materials

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 26802

License Grant
In March 20, 2003, the Company acquired all of Licensor's raw materials, work-in-progress and finished product of Alferon N Injection®, together with a limited license for the production, manufacture, use, marketing and sale of Alferon N Injection® interferon alfa-n3 (human derived) is a natural alpha interferon that has been approved by the U.S. Food and Drug Administration(FDA) for commercial sale for the treatment of certain types of genital warts was granted. On October 10, 1989, the FDA approved Alferon N Injection for the intralesional (within lesions) treatment of refractory (resistant to other treatment) or recurring external genital warts in patients 18 years of age or older. A subsequent agreement (as of 12/2002 had not closed) was to sell all rights to the product to licensee. The royalty negotiated was the same for both transactions.

IPSCIO Record ID: 26833

License Grant
On March 11, 2003, two agreements were executed to sell certain assets. The agreements involved inventory related to Alferon N Injection(R), a natural alpha interferon product approved for the treatment of certain types of genital warts (the Product), and granted a limited license for the production, manufacture, use, marketing and sale of the Product in the United States. This transaction is part of an amended asset purchase agreement. Both parties are U.S. corporations. A limited license has been granted for the United States. As part of the deal, the purchaser will pay royalties on the sales of the technology.
Field of Use
The relevant technology is Alferon N Injection ®; a natural alpha interferon product approved for the treatment of certain types of genital warts.

IPSCIO Record ID: 7773

License Grant
The Licensor, a subsidiary of Licensee, granted a worldwide, exclusive license, with the right to grant sublicenses, to use all of the Licensee's know-how, patent rights, and biological materials developed during the development period for all purposes other than the development, manufacture, or sale of the Product.  

Licensee granted a worldwide, nonexclusive license, with the right to grant sublicenses, to use all of Licensee's know-how, patent rights and biological materials.

License Property
ALFERON N Injection is approved for the intralesional treatment of adults with refractory (resistant to other treatment) or recurring external genital warts.
Field of Use
The Licensor's products under development include (i) expansion of the approved uses of ALFERON N Injection for the potential treatment of HIV, hepatitis C, hepatitis B, multiple sclerosis, cancers, and other indications

The business of the Licensee is to develop externally applied formulations of alpha interferon produced by recombinant DNA techniques to be used in the treatment of herpes genitalis (the Product), to develop large-scale processes for the formulation of the Product, to establish the safety and efficacy of the Product through clinical testing, to obtain the regulatory approvals necessary for the manufacture and sale of the Product, and to earn income from the worldwide sale of the Product.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.